Moderna stock slides premarket after 11% surge on flu vaccine filings

7 January 2026

New York, January 7, 2026, 05:25 EST — Premarket

Moderna (MRNA) shares fell 1.4% to $35.15 in premarket trading on Wednesday, after jumping 10.9% in the previous session to close at $35.66. The stock hit an intraday high of $36.26 on Tuesday, with about 20.2 million shares traded.

The moves follow Moderna’s announcement on Monday that it has filed for marketing authorization — regulatory approval to sell — for its messenger RNA (mRNA) seasonal influenza vaccine, mRNA-1010, in the United States, Europe, Canada and Australia. Moderna said the filings were backed by Phase 3 data showing relative vaccine efficacy — a head-to-head measure — of 26.6% in adults aged 50 and older. CEO Stéphane Bancel said, “If approved, this potential new product launch and geographic expansion represent an important opportunity to support Moderna’s continued growth in 2027 and beyond.” Nasdaq

Investors have been looking for signs that Moderna can extend its business beyond the pandemic-era boom and build steadier demand from seasonal shots. In a shareholder letter released on Monday, Moderna reiterated it was aiming for 2025 revenue of $1.6 billion to $2.0 billion and highlighted uptake of its three approved products — Spikevax for COVID-19, mRESVIA for RSV (respiratory syncytial virus) and its next-generation COVID vaccine mNEXSPIKE. The company also pointed to oncology as a longer-term driver and flagged five-year Phase 2b melanoma data in early 2026 for its individualized cancer vaccine candidate, intismeran, which it is developing with Merck.

Moderna is pushing into a flu market dominated by established vaccine makers, and it has argued its platform can better match strains that mutate through a season. In June, the company said mRNA-1010 was 26.6% more effective than a licensed influenza vaccine from GSK in adults aged 50 and older in a late-stage study.

The stock also drew support this week from Wall Street research. Moderna was up about 7% by mid-session on Tuesday after BofA Global Research raised its price objective, helping healthcare lead gains on Wall Street, a Reuters report showed. Broader markets are also braced for the week’s U.S. jobs report, a key input for bets on the Federal Reserve’s rate path.

But the rally comes with fresh legal noise. Bayer’s Monsanto unit sued Moderna and other COVID-19 vaccine makers in U.S. court on Tuesday, alleging patent infringement tied to mRNA technology. Moderna said it was aware of the lawsuit and would defend itself.

Shan Ahmed Khan Latest posts

Shan Ahmed Khan is a senior markets reporter at TS2.tech. His coverage ranges from stocks and technology to economic developments across global markets. He worked in investment research and market analysis before becoming a financial journalist and is a graduate of the Lahore University of Management Sciences (LUMS).

View all